Abstract
Serotonin, a biologically active amine, is related to carcinoid syndrome in functioning neuroendocrine tumors (NETs). Telotristat ethyl is a novel inhibitor of the tryptophan hydroxylase (TPH), a key enzyme in the production of serotonin. While its use in patients with carcinoid syndrome and uncontrolled diarrhea under somatostatin analogs (SSAs) has been recently approved, in vitro data evaluating its effectiveness are lacking. For this reason, we aimed to evaluate the effect of telotristat as monotherapy, and in combination with SSAs, on proliferation and secretion in a NET cell line model. The human pancreatic NET cell lines BON-1/QGP-1 were used as 2D and 3D cultured models; somatostatin receptor and TPH mRNA expression, as well as the potential autocrine effect of serotonin on tumor cell proliferation using a 3D culture system were evaluated. Telotristat decreased serotonin production in a dose-dependent manner at a clinically feasible concentration, without affecting cell proliferation. Its combination with pasireotide, but not with octreotide, had an additive inhibitory effect on serotonin secretion. The effect of telotristat was slightly less potent, when BON-1 cells were co-treated with octreotide. Octreotide and pasireotide had no effect on the expression of TPH. Telotristat did not have an effect on mRNA expression of somatostatin receptor subtypes. Finally, we showed that serotonin did not have an autocrine effect on NET cell proliferation on the 3D cell model. These results suggest that telotristat is an effective drug for serotonin inhibition, but the effectiveness of its combination with SST2 (somatostatin receptor subtype 2)-preferring SSA should be evaluated in more detail.
References
1.
Schnirer
II
2nd, Yao
JC
, Ajani
JA
. Carcinoid—a comprehensive review
. Acta Oncol
. 2003
;42
(7
):672
–92
.
[PubMed]
0284-186X2.
de Herder
WW
. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)
. Best Pract Res Clin Gastroenterol
. 2005
Oct
;19
(5
):705
–15
.
[PubMed]
1521-69183.
Best
J
, Nijhout
HF
, Reed
M
. Serotonin synthesis, release and reuptake in terminals: a mathematical model
. Theor Biol Med Model
. 2010
Aug
;7
(1
):34
.
[PubMed]
1742-46824.
Rorstad
O
. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract
. J Surg Oncol
. 2005
Mar
;89
(3
):151
–60
.
[PubMed]
0022-47905.
Kulke
MH
, Shah
MH
, Benson
AB
3rd, Bergsland
E
, Berlin
JD
, Blaszkowsky
LS
, et al.; National comprehensive cancer network
. Neuroendocrine tumors, version 1.2015
. J Natl Compr Canc Netw
. 2015
Jan
;13
(1
):78
–108
.
[PubMed]
1540-14056.
van der Lely
AJ
, de Herder
WW
. Carcinoid syndrome: diagnosis and medical management
. Arq Bras Endocrinol Metabol
. 2005
Oct
;49
(5
):850
–60
.
[PubMed]
0004-27307.
Zandee
WT
, Kamp
K
, van Adrichem
RC
, Feelders
RA
, de Herder
WW
. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours
. Eur J Endocrinol
. 2016
Nov
;175
(5
):361
–6
.
[PubMed]
0804-46438.
Kulke
MH
, Hörsch
D
, Caplin
ME
, Anthony
LB
, Bergsland
E
, Öberg
K
, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
. J Clin Oncol
. 2017
Jan
;35
(1
):14
–23
.
[PubMed]
0732-183X9.
O’Toole
D
, Ducreux
M
, Bommelaer
G
, Wemeau
JL
, Bouché
O
, Catus
F
, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance
. Cancer
. 2000
Feb
;88
(4
):770
–6
.
[PubMed]
0008-543X10.
Ruszniewski
P
, Ish-Shalom
S
, Wymenga
M
, O’Toole
D
, Arnold
R
, Tomassetti
P
, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
. Neuroendocrinology
. 2004
;80
(4
):244
–51
.
[PubMed]
0028-383511.
Janson
ET
, Oberg
K
. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon
. Acta Oncol
. 1993
;32
(2
):225
–9
.
[PubMed]
0284-186X12.
Plöckinger
U
, Wiedenmann
B
. Neuroendocrine tumors. Biotherapy
. Best Pract Res Clin Endocrinol Metab
. 2007
Mar
;21
(1
):145
–62
.
[PubMed]
1521-690X13.
Liu
Q
, Yang
Q
, Sun
W
, Vogel
P
, Heydorn
W
, Yu
XQ
, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract
. J Pharmacol Exp Ther
. 2008
Apr
;325
(1
):47
–55
.
[PubMed]
0022-356514.
Lapuerta Pablo
ZB
. Fleming Doug, Wheeler Darren, Sands Arthur, Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid sy ndrome
. Clin Investig (Lond)
. 2015
;5
(5
):447
–56
. 2041-679215.
Pavel
M
, Gross
DJ
, Benavent
M
, Perros
P
, Srirajaskanthan
R
, Warner
RR
, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
. Endocr Relat Cancer
. 2018
Mar
;25
(3
):309
–22
.
[PubMed]
1351-008816.
–.
[i.d.o.g.m.a.u.R.E.N.o.t.E.P.a.o.t.C.f.X.]
. E
. •••
;C
:C
.1046-802117.
FDA News Release
. 2017
FDA Approves Xermelo for Carcinoid Syndrome Diarrhea.
Silver Springs, M., USA: FDA. (available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm544035.htm)18.
National Comprehensive Cancer Network 2017 Neuroendocrine tumors (version 3.
2017
). Fort Washington, P., USA: NCCN. (available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf)19.
Kaku
M
, Nishiyama
T
, Yagawa
K
, Abe
M
. Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma
. Gan
. 1980
Oct
;71
(5
):596
–601
.
[PubMed]
0016-450X20.
La Rosa
S
, Franzi
F
, Albarello
L
, Schmitt
A
, Bernasconi
B
, Tibiletti
MG
, et al. Serotonin-producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors
. Pancreas
. 2011
Aug
;40
(6
):883
–95
.
[PubMed]
0885-317721.
Walter
T
, Hervieu
V
, Adham
M
, Gincul
R
, Poncet
G
, Pilleul
F
, et al. Primary neuroendocrine tumors of the main pancreatic duct: a rare entity
. Virchows Arch
. 2011
May
;458
(5
):537
–46
.
[PubMed]
0945-631722.
Tsoukalas
N
, Chatzellis
E
, Rontogianni
D
, Alexandraki
KI
, Boutzios
G
, Angelousi
A
, et al. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): report of 5 cases and review of the literature
. Medicine (Baltimore)
. 2017
Apr
;96
(16
):e6201
.
[PubMed]
0025-797423.
Hofving
T
, Arvidsson
Y
, Almobarak
B
, Inge
L
, Pfragner
R
, Persson
M
, et al. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
. Endocr Relat Cancer
. 2018
Mar
;25
(3
):367
–80
.
[PubMed]
1351-008824.
Tran
VS
, Marion-Audibert
AM
, Karatekin
E
, Huet
S
, Cribier
S
, Guillaumie
K
, et al. Serotonin secretion by human carcinoid BON cells
. Ann N Y Acad Sci
. 2004
Apr
;1014
(1
):179
–88
.
[PubMed]
0077-892325.
Doihara
H
, Nozawa
K
, Kojima
R
, Kawabata-Shoda
E
, Yokoyama
T
, Ito
H
. QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells
. Mol Cell Biochem
. 2009
Nov
;331
(1-2
):239
–45
.
[PubMed]
0300-817726.
Chen
X
, Shen
G
, Jiang
J
, Liu
H
, Hu
K
, Darstein
C
, et al. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study
. Clin Ther
. 2014
Aug
;36
(8
):1196
–210
.
[PubMed]
0149-291827.
Mohamed
A
, Blanchard
MP
, Albertelli
M
, Barbieri
F
, Brue
T
, Niccoli
P
, et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
. Endocr Relat Cancer
. 2014
Oct
;21
(5
):691
–704
.
[PubMed]
1351-008828.
Markham
A
. Telotristat Ethyl: First Global Approval
. Drugs
. 2017
May
;77
(7
):793
–8
.
[PubMed]
0012-666729.
Wängberg
B
, Nilsson
O
, Wigander
A
, Johansson
V
, Forssell-Aronsson
E
, Andersson
P
, et al. [Somatostatin receptors. A new way to diagnosis and therapy of neuroendocrine tumors]
. Lakartidningen
. 1997
Mar
;94
(10
):829
–30
.
[PubMed]
0023-720530.
Hofland
LJ
, van Koetsveld
PM
, Lamberts
SW
. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995
. Eur J Cancer
. 1990
Jan
;26
(1
):37
–44
.
[PubMed]
0959-804931.
Downs
TR
, Wilfinger
WW
. Fluorometric quantification of DNA in cells and tissue
. Anal Biochem
. 1983
Jun
;131
(2
):538
–47
.
[PubMed]
0003-269732.
O’Brien
MC
, Bolton
WE
. Comparison of cell viability probes compatible with fixation and permeabilization for combined surface and intracellular staining in flow cytometry
. Cytometry
. 1995
Mar
;19
(3
):243
–55
.
[PubMed]
0196-476333.
Ferone
D
, Pivonello
R
, Van Hagen
PM
, Dalm
VA
, Lichtenauer-Kaligis
EG
, Waaijers
M
, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes
. Am J Physiol Endocrinol Metab
. 2002
Nov
;283
(5
):E1056
–66
.
[PubMed]
0193-184934.
Meuer
S
, Wittwer
C
, Nakagawara
K
, editors. Rapid cycle real-time PCR, methods and applications
. Heidelberg
: Springer Press
; 2001
. pp. 21
–34
. 35.
Schmittgen
TD
, Livak
KJ
. Analyzing real-time PCR data by the comparative C(T) method
. Nat Protoc
. 2008
;3
(6
):1101
–8
.
[PubMed]
1754-218936.
Pfaffl
MW
. A new mathematical model for relative quantification in real-time RT-PCR
. Nucleic Acids Res
. 2001
May
;29
(9
):e45
.
[PubMed]
0305-104837.
Kulke
MH
, O’Dorisio
T
, Phan
A
, Bergsland
E
, Law
L
, Banks
P
, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
. Endocr Relat Cancer
. 2014
Oct
;21
(5
):705
–14
.
[PubMed]
1351-008838.
Pavel
M
, Hörsch
D
, Caplin
M
, Ramage
J
, Seufferlein
T
, Valle
J
, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial
. J Clin Endocrinol Metab
. 2015
Apr
;100
(4
):1511
–9
.
[PubMed]
0021-972X39.
Welford
RW
, Vercauteren
M
, Trébaul
A
, Cattaneo
C
, Eckert
D
, Garzotti
M
, et al. Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation
. Sci Rep
. 2016
Jul
;6
(1
):30059
.
[PubMed]
2045-232240.
Margolis
KG
, Stevanovic
K
, Li
Z
, Yang
QM
, Oravecz
T
, Zambrowicz
B
, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine
. Gut
. 2014
Jun
;63
(6
):928
–37
.
[PubMed]
0017-574941.
Kim
JJ
, Wang
H
, Terc
JD
, Zambrowicz
B
, Yang
QM
, Khan
WI
. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation
. Am J Physiol Gastrointest Liver Physiol
. 2015
Sep
;309
(6
):G455
–65
.
[PubMed]
0193-185742.
Pawlak
D
, Znorko
B
, Kalaska
B
, Domaniewski
T
, Zawadzki
R
, Lipowicz
P
, et al. LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys
. Bone
. 2018
Aug
;113
:124
–36
.
[PubMed]
8756-328243.
Full prescribing information: Xermelo. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf,
2017
.44.
Herrera-Martínez
AD
. F.R., Castaño JP, Van Dungen R, Dogan-Oruc F, Van Koetsveld P, Hofland LJ, Potential Effects of Ketoconazole on ACTHProducing and Non-ACTH-Producing Neuroendocrine Tumors.
ENETS Conference
, Abstract C06. Barcelona
., 2018
.45.
Veenstra
MJ
, van Koetsveld
PM
, Dogan
F
, Farrell
WE
, Feelders
RA
, Lamberts
SW
, et al. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells
. Oncotarget
. 2016
May
;9
(19
):14791
–802
.
[PubMed]
1949-255346.
Kvols
LK
, Oberg
KE
, O’Dorisio
TM
, Mohideen
P
, de Herder
WW
, Arnold
R
, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
. Endocr Relat Cancer
. 2012
Sep
;19
(5
):657
–66
.
[PubMed]
1351-008847.
Wolin
EM
, Jarzab
B
, Eriksson
B
, Walter
T
, Toumpanakis
C
, Morse
MA
, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
. Drug Des Devel Ther
. 2015
Sep
;9
:5075
–86
.
[PubMed]
1177-888148.
Cives
M
, Kunz
PL
, Morse
B
, Coppola
D
, Schell
MJ
, Campos
T
, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
. Endocr Relat Cancer
. 2015
Feb
;22
(1
):1
–9
.
[PubMed]
1351-008849.
de Herder
WW
, Hofland
LJ
, van der Lely
AJ
, Lamberts
SW
. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
. Endocr Relat Cancer
. 2003
Dec
;10
(4
):451
–8
.
[PubMed]
1351-008850.
Kanakis
G
, Grimelius
L
, Spathis
A
, Tringidou
R
, Rassidakis
GZ
, Öberg
K
, et al. Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
. Neuroendocrinology
. 2015
;101
(3
):211
–22
.
[PubMed]
0028-383551.
Herrera-Martínez
AD
, Gahete
MD
, Pedraza-Arevalo
S
, Sánchez-Sánchez
R
, Ortega-Salas
R
, Serrano-Blanch
R
, et al. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors
. Endocrine
. 2018
Feb
;59
(2
):426
–37
.
[PubMed]
1355-008X52.
Swami
T
, Weber
HC
. Updates on the biology of serotonin and tryptophan hydroxylase
. Curr Opin Endocrinol Diabetes Obes
. 2018
Feb
;25
(1
):12
–21
.
[PubMed]
1752-297853.
Sarrouilhe
D
, Clarhaut
J
, Defamie
N
, Mesnil
M
. Serotonin and cancer: what is the link?
Curr Mol Med
. 2015
;15
(1
):62
–77
.
[PubMed]
1566-524054.
Koba
S
, Pakala
R
, Watanabe
T
, Katagiri
T
, Benedict
CR
. Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins
. J Am Coll Cardiol
. 1999
Nov
;34
(5
):1644
–51
.
[PubMed]
0735-109755.
Banasr
M
, Hery
M
, Printemps
R
, Daszuta
A
. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone
. Neuropsychopharmacology
. 2004
Mar
;29
(3
):450
–60
.
[PubMed]
0893-133X56.
Liang
C
, Chen
W
, Zhi
X
, Ma
T
, Xia
X
, Liu
H
, et al. Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a
. Mol Cancer
. 2013
Feb
;12
(1
):14
.
[PubMed]
1476-459857.
Drozdov
I
, Kidd
M
, Gustafsson
BI
, Svejda
B
, Joseph
R
, Pfragner
R
, et al. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines
. Cancer
. 2009
Nov
;115
(21
):4934
–45
.
[PubMed]
0008-543X58.
Edmondson
R
, Broglie
JJ
, Adcock
AF
, Yang
L
. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors
. Assay Drug Dev Technol
. 2014
May
;12
(4
):207
–18
.
[PubMed]
1540-658X59.
Costa
EC
, Moreira
AF
, de Melo-Diogo
D
, Gaspar
VM
, Carvalho
MP
, Correia
IJ
. 3D tumor spheroids: an overview on the tools and techniques used for their analysis
. Biotechnol Adv
. 2016
Dec
;34
(8
):1427
–41
.
[PubMed]
0734-975060.
Cives
M
, Soares
HP
, Strosberg
J
. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials
. Curr Opin Oncol
. 2016
Jul
;28
(4
):359
–66
.
[PubMed]
1040-874661.
Spohn
SN
, Mawe
GM
. Non-conventional features of peripheral serotonin signalling - the gut and beyond
. Nat Rev Gastroenterol Hepatol
. 2017
Jul
;14
(7
):412
–20
.
[PubMed]
1759-504562.
Namkung
J
, Kim
H
, Park
S
. Peripheral Serotonin: a New Player in Systemic Energy Homeostasis
. Mol Cells
. 2015
Dec
;38
(12
):1023
–8
.
[PubMed]
1016-847863.
Martin
AM
, Young
RL
, Leong
L
, Rogers
GB
, Spencer
NJ
, Jessup
CF
, et al. The Diverse Metabolic Roles of Peripheral Serotonin
. Endocrinology
. 2017
May
;158
(5
):1049
–63
.
[PubMed]
0013-722764.
Herr
N
, Bode
C
, Duerschmied
D
. The Effects of Serotonin in Immune Cells
. Front Cardiovasc Med
. 2017
Jul
;4
:48
.
[PubMed]
2297-055X65.
Lima
GM
, Corazza
BJ
, Moraes
RM
, de Oliveira
FE
, de Oliveira
LD
, Franco
GC
, et al. The effect of an inhibitor of gut serotonin (LP533401) during the induction of periodontal disease
. J Periodontal Res
. 2016
Oct
;51
(5
):661
–8
.
[PubMed]
0022-348466.
van der Horst-Schrivers
AN
, Wymenga
AN
, Links
TP
, Willemse
PH
, Kema
IP
, de Vries
EG
. Complications of midgut carcinoid tumors and carcinoid syndrome
. Neuroendocrinology
. 2004
;80
Suppl 1
:28
–32
.
[PubMed]
0028-383567.
Siddique
ZL
, Drozdov
I
, Floch
J
, Gustafsson
BI
, Stunes
K
, Pfragner
R
, et al. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model
. Neuroendocrinology
. 2009
;89
(4
):458
–70
.
[PubMed]
0028-3835© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
